Oblato, Inc.
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
- Conditions
- High-grade GliomaOligodendrogliomaAstrocytomaGlioblastoma Multiforme
- Interventions
- Drug: Mid-dose OKN-007, TIDDrug: High-dose OKN-007, TIDDrug: Low-dose OKN-007, BIDDrug: Low-dose OKN-007, TID
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Oblato, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05561374
- Locations
- 🇺🇸
Providence Saint John's Cancer Institute, Santa Monica, California, United States
🇺🇸Norton Healthcare, Louisville, Kentucky, United States
🇺🇸Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
- Conditions
- Diffuse Midline Glioma, H3 K27M-MutantDiffuse Intrinsic Pontine Glioma
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Oblato, Inc.
- Registration Number
- NCT05518838
- Locations
- 🇺🇸
Arkansas Children's Research Institute, Little Rock, Arkansas, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Arnold Palmer Hospital for Children, Orlando, Florida, United States
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
- Conditions
- Brain GlioblastomaRecurrent Malignant Glioma
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Oblato, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04388475
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Providence Saint John's Health Center - John Wayne Cancer Institute, Santa Monica, California, United States
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Oblato, Inc.
- Registration Number
- NCT03649464
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Oblato, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01672463
- Locations
- 🇺🇸
Oklahoma University, Oklahoma City, Oklahoma, United States